Literature DB >> 20297856

For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians.

Tami L Mark1.   

Abstract

BACKGROUND: Psychoactive medications, such as antidepressants, are one of the most widely prescribed categories of drugs in the US; yet few studies have comprehensively examined the conditions for which psychoactive medications are prescribed. To our knowledge, no prior study has examined the extent to which psychoactive medications are prescribed for non-psychiatric somatic illnesses or the main types of psychiatric disorders for which psychoactive medications are being used.
OBJECTIVE: To examine the diagnoses for which psychiatric medications are being prescribed in the US by analysing data from a nationally representative survey of physicians.
METHODS: The data were obtained from the 2005 National Disease and Therapeutic Index (NDTI), a continuing survey of a US office-based panel of physicians. The 2005 physician panel consisted of approximately 4000 physicians reporting quarterly, which was projected to a universe of 500,722 physicians. The study focused on the diagnoses that were given as the primary reason for prescribing the following types of psychotropic medications: antidepressants, antipsychotics and anti-anxiety medications.
RESULTS: Of the total number of antidepressant drug mentions, 92.7% were prescribed for psychiatric conditions. The most common (65.3%) were mood disorders (e.g. depression), followed by anxiety disorders (16.4%), which together comprised 81.7% of all antidepressant drug mentions. Of the total number of anti-anxiety drug mentions, 67.7% were prescribed for psychiatric conditions. The most common diagnosis was anxiety disorders (comprising 39.6% of all drug mentions), followed by mood disorders (comprising 18.9% of all drug mentions). Almost one-third of anxiety medication drug mentions were for non-psychiatric conditions or conditions of unspecified type. Of the total number of antipsychotic drug mentions, 98.9% were prescribed for psychiatric conditions. The most common diagnoses, comprising 39.0% of all drug mentions, were mood disorders such as depression and bipolar disorder. The second most common psychiatric diagnosis was schizophrenia or other psychotic disorders, comprising 34.5% of drug mentions. Approximately 7.4% of drug mentions were for delirium, dementia, amnestic or other cognitive disorders. Attention-deficit/conduct/disruptive behaviour disorders were the diagnoses indicated on 5.7% of all antipsychotic drug mentions. Anxiety disorders were indicated on 5.5% of antipsychotic drug mentions. Disorders usually diagnosed in infancy/childhood/adolescence (e.g. autism) comprised 2.3% of antipsychotic drug mentions.
CONCLUSIONS: This research provides a broad view of the nature of psychoactive medication prescribing, which may serve as a guide to future research, policy and education about these medications, their perceived benefits and risks, and their uses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20297856     DOI: 10.2165/11533120-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  10 in total

1.  Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001.

Authors:  Samuel H Zuvekas
Journal:  Health Aff (Millwood)       Date:  2005 Jan-Feb       Impact factor: 6.301

Review 2.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  Mental health treatment expenditure trends, 1986-2003.

Authors:  Tami L Mark; Katharine R Levit; Jeffrey A Buck; Rosanna M Coffey; Rita Vandivort-Warren
Journal:  Psychiatr Serv       Date:  2007-08       Impact factor: 3.084

4.  Off-label prescribing among office-based physicians.

Authors:  David C Radley; Stan N Finkelstein; Randall S Stafford
Journal:  Arch Intern Med       Date:  2006-05-08

5.  Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype.

Authors:  H M Pettinati; J R Volpicelli; H R Kranzler; G Luck; M R Rukstalis; A Cnaan
Journal:  Alcohol Clin Exp Res       Date:  2000-07       Impact factor: 3.455

Review 6.  Marijuana neurobiology and treatment.

Authors:  Ahmed Elkashef; Frank Vocci; Marilyn Huestis; Margaret Haney; Alan Budney; Amanda Gruber; Nady el-Guebaly
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

7.  Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics.

Authors:  Maggie Nellissery; Richard S Feinn; Jonathan Covault; Joel Gelernter; Raymond F Anton; Helen Pettinati; Darlene Moak; Timothy Mueller; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2003-09       Impact factor: 3.455

Review 8.  Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.

Authors:  Carl Salzman; Dilip V Jeste; Roger E Meyer; Jiska Cohen-Mansfield; Jeffrey Cummings; George T Grossberg; Lissy Jarvik; Helena C Kraemer; Barry D Lebowitz; Katie Maslow; Bruce G Pollock; Murray Raskind; Susan K Schultz; Philip Wang; Julie M Zito; George S Zubenko
Journal:  J Clin Psychiatry       Date:  2008-06       Impact factor: 4.384

9.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Authors:  Clive Ballard; Maria Luisa Hanney; Megan Theodoulou; Simon Douglas; Rupert McShane; Katja Kossakowski; Randeep Gill; Edmund Juszczak; Ly-Mee Yu; Robin Jacoby
Journal:  Lancet Neurol       Date:  2009-01-08       Impact factor: 44.182

10.  Bupropion for the treatment of methamphetamine dependence.

Authors:  Ahmed M Elkashef; Richard A Rawson; Ann L Anderson; Shou-Hua Li; Tyson Holmes; Edwina V Smith; Nora Chiang; Roberta Kahn; Frank Vocci; Walter Ling; Valerie J Pearce; Michael McCann; Jan Campbell; Charles Gorodetzky; William Haning; Barry Carlton; Joseph Mawhinney; Dennis Weis
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

  10 in total
  17 in total

1.  Psychotropic medication claims among religious clergy.

Authors:  Steven M Frenk; Sarah A Mustillo; Steven L Foy; Whitney D Arroyave; Elizabeth G Hooten; Kari H Lauderback; Keith G Meador
Journal:  Psychiatr Q       Date:  2013-03

2.  Antidepressant use and lifetime history of mental disorders in a community sample: results from the Baltimore Epidemiologic Catchment Area Study.

Authors:  Yoichiro Takayanagi; Adam P Spira; O Joseph Bienvenu; Rebecca S Hock; Michelle C Carras; William W Eaton; Ramin Mojtabai
Journal:  J Clin Psychiatry       Date:  2015-01       Impact factor: 4.384

3.  Does Early-Life Misfortune Increase the Likelihood of Psychotropic Medication Use in Later Life?

Authors:  Patricia M Morton; Kenneth F Ferraro
Journal:  Res Aging       Date:  2017-06-29

4.  Effect of documented and undocumented psychiatric conditions on length of stay and discharge destination after total knee arthroplasty.

Authors:  Katherine A Lygrisse; Vivek Singh; Christian T Oakley; Alex Tang; Stephen G Zak; Andrew J Clair; Claudette M Lajam
Journal:  Arch Orthop Trauma Surg       Date:  2022-03-23       Impact factor: 3.067

Review 5.  Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

Authors:  Jeremy D Coplan; Cindy J Aaronson; Venkatesh Panthangi; Younsuk Kim
Journal:  World J Psychiatry       Date:  2015-12-22

Review 6.  Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

Authors:  Alexander C Tsai; Nicholas Z Rosenlicht; Jon N Jureidini; Peter I Parry; Glen I Spielmans; David Healy
Journal:  PLoS Med       Date:  2011-05-03       Impact factor: 11.069

7.  Polypharmacy or medication washout: an old tool revisited.

Authors:  Daniel A Hoffman; Mark Schiller; James M Greenblatt; Dan V Iosifescu
Journal:  Neuropsychiatr Dis Treat       Date:  2011-10-20       Impact factor: 2.570

8.  Is retirement beneficial for mental health?: antidepressant use before and after retirement.

Authors:  Tuula Oksanen; Jussi Vahtera; Hugo Westerlund; Jaana Pentti; Noora Sjösten; Marianna Virtanen; Ichiro Kawachi; Mika Kivimäki
Journal:  Epidemiology       Date:  2011-07       Impact factor: 4.822

9.  Multi-exposure and clustering of adverse childhood experiences, socioeconomic differences and psychotropic medication in young adults.

Authors:  Emma Björkenstam; Anders Hjern; Ellenor Mittendorfer-Rutz; Bo Vinnerljung; Johan Hallqvist; Rickard Ljung
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

10.  Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study.

Authors:  Shannon Hughes; David Cohen; Rachel Jaggi
Journal:  BMJ Open       Date:  2014-07-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.